|
Aug 7
|
GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
|
|
Jul 30
|
GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
|
|
Jul 29
|
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
|
|
Jul 29
|
Geovax Labs Inc (GOVX) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
|
|
Jul 28
|
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Jul 28
|
GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
|
|
Jul 24
|
GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results
|
|
Jul 22
|
GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025
|
|
Jul 21
|
GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
|
|
Jul 16
|
GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
|
|
Jul 15
|
Presenting on Emerging Growth Conference 84 Day 1 on July 16; Register to live stream
|
|
Jul 14
|
GeoVax to Present at the Emerging Growth Conference on July 16, 2025
|
|
Jul 2
|
GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives
|
|
Jul 1
|
GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering
|
|
Jun 25
|
GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
|
|
Jun 17
|
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
|
|
Jun 12
|
GeoVax to Participate in BIO International Convention 2025
|
|
Jun 11
|
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency
|
|
Jun 10
|
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
|
|
Jun 9
|
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
|